Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Nanobodies blocking immunosuppressive unexplored proteins from the tumor endothelium to promote anti-tumor immune response

Project description

Nanobody-based reprogramming of the tumour vasculature to restore anti-tumour immunity

Harnessing the immune system to fight cancer is promising, but up to 80 % of non-small cell lung cancer patients do not respond or develop resistance to current therapies. These treatments often overlook endothelial cells, despite their emerging role in tumour immune evasion. The ERC-funded NANOBITER project builds on research that identified 26 immunosuppressive genes specific to endothelial cells, using AI tools and mouse models. NANOBITER aims to develop nanobody therapeutics targeting three of the most promising secreted or membrane-exposed targets. Expanding druggable targets beyond cancer and immune cells has shown potential to enhance anti-tumour immunity and slow tumour growth in laboratory studies. Project work could lead to more effective lung cancer treatments and a significant shift in cancer therapy.

Objective

"In non-small cell lung cancer (NSCLC), approximately 80% of patients have a poor response or develop resistance to current immunotherapies (IT), highlighting a critical need for more effective treatments. To date, most ITs focus on targeting cancer or immune cells, often overlooking endothelial cells (ECs), the body's largest organ. In the running ERC Adv Grant project MystIMEC (#101055155), we demonstrated the immunosuppressive nature of tumor ECs and their pathobiological role in tumor progression. With up to 90% of new drug candidates failing in clinical trials, often due to suboptimal target selection, the host lab has taken a fundamentally different approach to discovering novel therapeutic targets. Leveraging cutting-edge in-house developed AI and gene prioritization tools together with EC-selective lipid nanoparticle-based genetic silencing in a mouse lung tumor model, we discovered and validated 26 previously unexplored immunosuppressive genes (with poor functional annotation, ca 1/3 of human coding genome) as candidate therapeutic targets specific to ECs: silencing these genes promotes anti-tumor immune responses and reduces tumor growth. This ERC-PoC proposal builds further on these findings, aiming to develop nanobody (Nb) therapeutics for three promising targets with the greatest therapeutic efficacy. These targets are either secreted or membrane-exposed and therefore amenable to Nb-based inhibition, a treatment modality successfully used in the clinic. The results will provide the first Proof-of-Concept that our visionary approach to discover and validate unexplored immunosuppressive genes is an efficient, innovative, game-changing strategy. After generating Nbs, we will screen for the top two candidates with the strongest neutralizing effects in vitro (amongst other criteria). Finally, as Proof-of-Concept, the two selected Nbs will be validated in an in vivo lung tumor model for their efficacy to enhance anti-tumor immunity and to reduce tumor growth."

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

VIB VZW
Net EU contribution
€ 150 000,00
Address
SUZANNE TASSIERSTRAAT 1
9052 ZWIJNAARDE - GENT
Belgium
Region
Vlaams Gewest Prov. Oost-Vlaanderen Arr. Gent
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)